Lymphadenopathy epidemiology and demographics

Jump to navigation Jump to search

Lymphadenopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lymphadenopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lymphadenopathy epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphadenopathy epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphadenopathy epidemiology and demographics

CDC on Lymphadenopathy epidemiology and demographics

Lymphadenopathy epidemiology and demographics in the news

Blogs on Lymphadenopathy epidemiology and demographics

Directions to Hospitals Treating Lymphadenopathy

Risk calculators and risk factors for Lymphadenopathy epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2] Raviteja Guddeti, M.B.B.S. [3] Delband Yekta Moazami, M.D.[4] Ogechukwu Hannah Nnabude, MD

Overview

The estimated incidence of lymphadenopathy in children in the United States ranges from 35%- 45%. It is more common in the pediatric population. Race and gender have no predilection in lymphadenopathy incidence.

Epidemiology and Demographics

Incidence

  • The estimated incidence of lymphadenopathy among children in the United States ranges from 35%- 45%.[1]

Age

Gender

  • Lymphadenopathy affects men and women equally.

Race

The epidemiology of lymphadenopathy may safely be made up of generalities.[2] [3] [4]

First, without regard to gender, both generalized and localized lymphadenopathies are fairly equal in distribution. Second, in the pediatric population, lymphadenopathy is more prevalent than in the adult population, due to a higher number of viral infections. It will follow that, in the pediatric population, lymphadenopathy is again secondary to the prevalence of viral and bacterial infections in that age group for the majority of the time. Three-quarters of all observed lymphadenopathies are localized, and half of the three-quarters are localized to the area of the head and neck. In the inguinal region, all remaining localized lymphadenopathy is located, and in the supraclavicular area, the remaining lymphadenopathy is found in the axilla. notable, with the age of the patient, the differential diagnosis of lymphadenopathy varies dramatically. In the inguinal region, all remaining localized lymphadenopathy is located, and in the supraclavicular area, the remaining lymphadenopathy is found in the axilla. Of note, with the age of the patient, the differential diagnosis of lymphadenopathy varies dramatically.

Third, the position and situation of the patient are very revealing, and lymphadenopathy. For example, parasite exposure, HIV, and military TB are much more likely to be causes of generalized lymphadenopathy in the developing world (sub-Saharan Africa, Southeast Asia, Indian subcontinent), than in the United States and Europe. Since, in the United States and the rest of the localized developed world, Epstein-Barr virus, streptococcal pharyngitis, and other neoplastic processes are more likely candidates to induce lymphadenopathy. For diagnosis, an exposure history is very relevant.

  • Exposure, either by transfusion, unhealthy sexual habits, intravenous substance abuse, or vocation
  • Exposure to infectious disease whether it be travel, in the workplace, or the home
  • Medication exposure-prescription, nonprescription, or supplements
  • Exposure either via pets or the workplace to animal-borne illness
  • Exposure to bites from arthropods

References

  1. 1.0 1.1 Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A (2014). "Peripheral lymphadenopathy: approach and diagnostic tools". Iran J Med Sci. 39 (2 Suppl): 158–70. PMC 3993046. PMID 24753638.
  2. Siddiqui S, Osher J (2017). "Assessment of Neck Lumps in Relation to Dentistry". Prim Dent J. 6 (3): 44–50. doi:10.1308/205016817821931079. PMID 30188316.
  3. Loizos A, Soteriades ES, Pieridou D, Koliou MG (2018). "Lymphadenitis by non-tuberculous mycobacteria in children". Pediatr Int. 60 (12): 1062–1067. doi:10.1111/ped.13708. PMID 30290041.
  4. Prudent E, La Scola B, Drancourt M, Angelakis E, Raoult D (2018). "Molecular strategy for the diagnosis of infectious lymphadenitis". Eur J Clin Microbiol Infect Dis. 37 (6): 1179–1186. doi:10.1007/s10096-018-3238-2. PMID 29594802.

Template:WH Template:WS